Mural Oncology (NASDAQ:MURA – Get Free Report) had its target price lowered by equities researchers at HC Wainwright from $18 ...

Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...

H.C. Wainwright lowered the firm’s price target on Bitfarms (BITF) to $3.50 from $4 and keeps a Buy rating on the shares. The firm also added ...

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on PDS Biotechnology (PDSB) to $13 from $21 and keeps a Buy rating on ...

Fintel reports that on March 25, 2025, HC Wainwright & Co. downgraded their outlook for Opthea Limited - Depositary Receipt () (NasdaqGS:OPT) from Buy to Neutral. Analyst Price Forecast Suggests 95.62 ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...

On Thursday, H.C. Wainwright reiterated a Neutral rating on Lyell Immunopharma (NASDAQ:LYEL) shares, with a steady price target of $1.00. The stock, currently trading at $0.67, has experienced ...

On Tuesday, H.C. Wainwright reaffirmed its Buy rating on Viking Therapeutics (NASDAQ:VKTX), with a steady price target of $102.00. Currently trading at $27.96, the stock has significant upside ...

H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...

The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest cryptocurrency, broker H.C. Wainwright said in a research report Monday.

https://www.tipranks.com/news/the-fly/h-c-wainwright-says-novo-results-support-viking-obesity-potential H.C. Wainwright notes that Neutral-rated Cassava Sciences ...

Tuesday saw H.C. Wainwright analyst Raghuram Selvaraju reaffirm a Buy rating and a $15.00 price target for Emergent BioSolutions (NYSE:EBS) stock, which currently trades at $6.83. According to ...